Published in Breast Cancer Res on January 01, 2006
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One (2010) 1.43
Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol Oncol (2007) 1.02
Optimizing performance of glycopeptide capture for plasma proteomics. J Proteome Res (2010) 0.91
Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. J Hematol Oncol (2010) 0.86
Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. Br J Cancer (2010) 0.86
Proteomic approaches and identification of novel therapeutic targets for alcoholism. Neuropsychopharmacology (2013) 0.85
Molecular targets of alcohol action: Translational research for pharmacotherapy development and screening. Prog Mol Biol Transl Sci (2011) 0.83
Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer. Invest Ophthalmol Vis Sci (2015) 0.79
The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics (2002) 16.08
Laser capture microdissection. Science (1996) 12.21
Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol (2003) 6.86
Proteomic analysis of post-translational modifications. Nat Biotechnol (2003) 5.87
Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med (2001) 2.49
Gene expression perturbation in vitro--a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol (2005) 2.35
Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) (1996) 1.84
Tissue profiling by mass spectrometry: a review of methodology and applications. Mol Cell Proteomics (2005) 1.64
Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics (2005) 1.59
Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics (2004) 1.57
Imaging mass spectrometry: principles and potentials. Toxicol Pathol (2005) 1.54
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res (2004) 1.36
Place of pattern in proteomic biomarker discovery. J Proteome Res (2005) 1.32
A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics (2005) 1.08
Proteomics in the forefront of cancer biomarker discovery. J Proteome Res (2005) 0.92
Towards discovery-driven translational research in breast cancer. FEBS J (2005) 0.90
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem (2002) 3.34
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell (2007) 3.02
Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat Genet (2006) 2.92
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat Biotechnol (2012) 2.14
Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res (2006) 2.10
Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem (2002) 2.08
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
Mining gene expression databases for association rules. Bioinformatics (2003) 2.06
Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res (2007) 2.04
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology (2002) 1.62
Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum (2004) 1.61
DNA methylation and chromatin structure regulate T cell perforin gene expression. J Immunol (2003) 1.54
Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res (2008) 1.53
Profiling of the cell surface proteome. Proteomics (2003) 1.38
T cell chemokine receptor expression in aging. J Immunol (2003) 1.32
The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas (2004) 1.31
Pancreatic gene expression during the initiation of acute pancreatitis: identification of EGR-1 as a key regulator. Physiol Genomics (2003) 1.28
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer (2004) 1.26
Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2004) 1.23
Infrequent occurrence of age-dependent changes in CpG island methylation as detected by restriction landmark genome scanning. Mech Ageing Dev (2002) 1.21
DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol (2008) 1.21
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21
Standard guidelines for the chromosome-centric human proteome project. J Proteome Res (2012) 1.20
Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol (2003) 1.20
Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics (2003) 1.13
Ovarian cancer early detection claims are biased. Clin Cancer Res (2008) 1.10
Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol (2003) 1.08
Candidate downstream regulated genes of HOX group 13 transcription factors with and without monomeric DNA binding capability. Dev Biol (2005) 1.06
The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A (2009) 1.06
An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology (2002) 1.06
Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology (2006) 1.05
A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. J Proteome Res (2012) 1.03
Inducible expression of macrophage receptor Marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays. J Immunol (2003) 1.01
Aging is associated with increased T-cell chemokine expression in C57BL/6 mice. J Gerontol A Biol Sci Med Sci (2003) 1.00
Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia (2002) 0.98
Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res (2012) 0.98
A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem (2011) 0.96
Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers (2004) 0.96
Peptide sequence confidence in accurate mass and time analysis and its use in complex proteomics experiments. J Proteome Res (2008) 0.96
Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res (2007) 0.94
Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res (2005) 0.92
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res (2005) 0.91
Innovative proteomic approaches for cancer biomarker discovery. Biotechniques (2007) 0.91
Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol (2003) 0.90
Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology (2004) 0.90
CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology (2005) 0.89
Integrated genomic and proteomic analysis of signaling pathways in dendritic cell differentiation and maturation. Ann N Y Acad Sci (2002) 0.88
Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol (2013) 0.88
Gene expression patterns define pathways correlated with loss of differentiation in lung adenocarcinomas. FEBS Lett (2003) 0.87
Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia (2002) 0.87
CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol (2013) 0.86
Familial molar tissues due to mutations in the inflammatory gene, NALP7, have normal postzygotic DNA methylation. Hum Genet (2006) 0.86
Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron (2008) 0.86
Protein quantification by mass spectrometry: is it ready for prime time? Clin Chem (2009) 0.84
Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol (2015) 0.83
Circulating pro-surfactant protein B as a risk biomarker for lung cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.83
Comprehensive profiling of the cell surface proteome of Sy5Y neuroblastoma cells yields a subset of proteins associated with tumor differentiation. J Proteome Res (2009) 0.83
Proteomic global profiling for cancer biomarker discovery. Methods Mol Biol (2009) 0.81
Quantitative serum proteomics using dual stable isotope coding and nano LC-MS/MSMS. J Proteome Res (2009) 0.81
Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications. Nat Protoc (2011) 0.80
An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays. Proteomics Clin Appl (2007) 0.79
Comprehensive proteomic profiling of aldehyde dehydrogenases in lung adenocarcinoma cell lines. Int J Proteomics (2011) 0.79
Intact-protein analysis system for discovery of serum-based disease biomarkers. Methods Mol Biol (2011) 0.77
[From genome to proteome--aim of human proteomics]. Seikagaku (2004) 0.77
A genome scanning approach to assess the genetic effects of radiation in mice and humans. Radiat Res (2004) 0.77
Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther (2012) 0.76
Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy. Proteomics Clin Appl (2013) 0.76
Unraveling the complex proteome for biomarker discovery in gastrointestinal and liver diseases. Gastroenterology (2006) 0.75
Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell (2016) 0.75
In-depth quantitative proteomics for pancreatic cancer biomarker discovery. Expert Opin Med Diagn (2007) 0.75